Treatment of irritable bowel syndrome in China: a review
- PMID: 25741137
- PMCID: PMC4342906
- DOI: 10.3748/wjg.v21.i8.2315
Treatment of irritable bowel syndrome in China: a review
Abstract
Irritable bowel syndrome (IBS) is a common, chronic, functional gastrointestinal disorder with a high incidence rate in the general population, and it is common among the Chinese population. The pathophysiology, etiology and pathogenesis of IBS are poorly understood, with no evidence of inflammatory, anatomic, metabolic, or neoplastic factors to explain the symptoms. Treatment approaches are mainly focused on symptom management to maintain everyday functioning and to improve quality of life for patients with IBS. However, prescribed medications often result in significant side effects, and many IBS sufferers (particularly Chinese) do not improve. Instead of taking a variety of conventional medications, many have turned to taking traditional Chinese medicine or integrated Chinese and Western medicine for remedy. A number of clinical trials have shown that Chinese herbal, acupuncture or integrative therapies presented improved treatment outcomes and reduced side effects in IBS patients. The purpose of this review article is to examine the treatment approaches of IBS that have been published in recent years, especially in China, to assess the possible differences in treating IBS between China and other countries. This would provide some useful information of unique treatment approach in clinical practice for physicians in the management of IBS in China, thus offering more treatment options for IBS patients with potentially better treatment outcomes while reducing the medical cost burden.
Keywords: China; Integrated treatment; Irritable bowel syndrome; Traditional Chinese medicine.
Figures
Similar articles
-
Management of irritable bowel syndrome (IBS) in adults: conventional and complementary/alternative approaches.Altern Med Rev. 2011 Jun;16(2):134-51. Altern Med Rev. 2011. PMID: 21649455 Review.
-
Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for health-care practitioners.J Gastroenterol Hepatol. 2010 Apr;25(4):691-9. doi: 10.1111/j.1440-1746.2009.06120.x. Epub 2010 Jan 13. J Gastroenterol Hepatol. 2010. PMID: 20074154 Review.
-
Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine.World J Gastroenterol. 2014 Jun 14;20(22):6759-73. doi: 10.3748/wjg.v20.i22.6759. World J Gastroenterol. 2014. PMID: 24944467 Free PMC article. Review.
-
The Efficacy and Potential Mechanisms of Chinese Herbal Medicine on Irritable Bowel Syndrome.Curr Pharm Des. 2017;23(34):5163-5172. doi: 10.2174/1381612823666170822101606. Curr Pharm Des. 2017. PMID: 28828984 Review.
-
Curcumin and Fennel Essential Oil Improve Symptoms and Quality of Life in Patients with Irritable Bowel Syndrome.J Gastrointestin Liver Dis. 2016 Jun;25(2):151-7. doi: 10.15403/jgld.2014.1121.252.ccm. J Gastrointestin Liver Dis. 2016. PMID: 27308645 Clinical Trial.
Cited by
-
Moxibustion treatment for diarrhea-predominant irritable bowel syndrome: study protocol for a randomized controlled trial.BMC Complement Altern Med. 2016 Oct 24;16(1):408. doi: 10.1186/s12906-016-1386-4. BMC Complement Altern Med. 2016. PMID: 27776494 Free PMC article. Clinical Trial.
-
Efficacy and Mechanism of Trimebutine Maleate Combined with Lactulose in the Treatment of Constipation-Predominant Irritable Bowel Syndrome in the Elderly.Emerg Med Int. 2022 Nov 11;2022:6125120. doi: 10.1155/2022/6125120. eCollection 2022. Emerg Med Int. 2022. Retraction in: Emerg Med Int. 2024 Jan 24;2024:9837328. doi: 10.1155/2024/9837328. PMID: 36406929 Free PMC article. Retracted.
-
Efficacy of Chinese Herbal Medicine for Diarrhea-Predominant Irritable Bowel Syndrome: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials.Evid Based Complement Alternat Med. 2016;2016:4071260. doi: 10.1155/2016/4071260. Epub 2016 Jul 31. Evid Based Complement Alternat Med. 2016. PMID: 27547226 Free PMC article. Review.
-
The characteristics of intestinal flora of IBS-D with different syndromes.Immun Inflamm Dis. 2020 Dec;8(4):615-628. doi: 10.1002/iid3.348. Epub 2020 Sep 17. Immun Inflamm Dis. 2020. PMID: 32940426 Free PMC article.
-
Network Pharmacology-Based Strategy to Investigate the Pharmacologic Mechanisms of Atractylodes macrocephala Koidz. for the Treatment of Chronic Gastritis.Front Pharmacol. 2020 Jan 29;10:1629. doi: 10.3389/fphar.2019.01629. eCollection 2019. Front Pharmacol. 2020. PMID: 32063848 Free PMC article.
References
-
- Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Quigley EM. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104 Suppl 1:S1–35. - PubMed
-
- Liu J, Hou X. A review of the irritable bowel syndrome investigation on epidemiology, pathogenesis and pathophysiology in China. J Gastroenterol Hepatol. 2011;26 Suppl 3:88–93. - PubMed
-
- Pan G, Lu S, Ke M, Han S, Guo H, Fang X. [An epidemiologic study of irritable bowel syndrome in Beijing - a stratified randomized study by clustering sampling] Zhonghua Liu Xing Bing Xue Zazhi. 2000;21:26–29. - PubMed
-
- Xiong LS, Chen MH, Chen HX, Xu AG, Wang WA, Hu PJ. [A population-based epidemiologic study of irritable bowel syndrome in Guangdong province] Zhonghua Yi Xue Zazhi. 2004;84:278–281. - PubMed
-
- Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical